MOSCOW, December 21. /TASS/. Russia’s Federal Medical-Biological Agency (FMBA) successfully completed pre-clinical studies of its newest medication for treating hepatitis C, which can be now clinically tested in 2018, the agency’s head, Vladimir Uiba, said during his press conference.
"The drug will be used to fight hepatitis C, a tremendous detriment to society that can decimate the working-age population. Today, there is a drug that exists in the world to treat hepatitis C, it … was developed two years ago, but it is extremely expensive and for 90% of the public, it is simply unaffordable. That’s why, we’ve created this drug to treat hepatitis C and completed the pre-clinical trials in 2017, which only proved its complete safety," he said.
Uiba further noted that the agency has put together the necessary package of documents, needed for the clinical trials.